This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

分子诊断学 2020-2030

技术、市场和预测

显示全部 说明 内容、图表列表 常见问题解答 价格 Related Content
随着技术的发展（如第三代 DNA 测序、数字 PCR 和微流体器件），即时分子诊断市场的增长，以及具有可靠临床实用性的基因生物标记的不断发现，分子诊断成为了医疗保健行业中增长最快的市场之一。到 2030 年，分子诊断市场的规模预计将达到 200 亿美元。
Molecular diagnostics (MDx) is used to assess an individual's health at the molecular level, analyzing specific genetic sequences encoded in deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or the proteins that are expressed from these genetic sequences. All disease is a result of genes interacting with the environment. MDx provide a golden path toward personalized health care, precision medicine and predictive health care.
 
 
Molecular diagnostics is the fastest growing segment of the broader diagnostics market. The market for MDx is expected to grow from $8.5 billion at present to around $20 billion by 2030. The growth of MDx is driven by the technology developments, the growth of the point-of-care MDx market, and the continued discovery of genetic biomarkers with proven clinical utility.
There are multiple techniques for testing genetic materials, some of which lend themselves more readily to miniaturization. Initially, molecular diagnostics were carried out using hybridization methods, such as fluorescence in situ hybridization. Later, polymerase chain reaction (PCR) and microarrays offered high throughput and more accurate tests. More recently DNA sequencing is an alternative for MDx as an unbiased and direct method. This report gives a comprehensive study and complete analysis of the important trends in the field of molecular diagnostics and particularly focuses on three categories of technologies and equipment:
 
• Microarrays:
• Polymerase chain reaction (PCR)
• DNA sequencing
 
For each technology category, this report summarises the technology advancements and innovations, lists the dominant companies and their key technologies, and provides ten-year forecasts on the market growth from 2020-2030. The forecasts are mainly built on information derived from historic data of key players, intensive company interviews, and the assumptions of the adoption rate of new technologies such as digital polymerase chain reaction and third generation sequencing.
Traditionally, molecular diagnostics has been used in life science research, infectious disease testing and cancer diagnostics, but the market of MDx is expanding into new areas, such as companion diagnostics, liquid biopsy, direct-to-consumer and more. The report gives a 10-year market forecast segmented by the following applications:
 
• Infectious disease
• Cancer and liquid biopsy
• Genetic testing
• Life science research
• Companion diagnostic
• Direct-to-consumer
 
This report provides 30 company profiles of the main players across different segments. It also gives a comprehensive study on both currently available and incoming devices. This report will be useful to any company wishing to know the molecular diagnostics market, advanced techniques and devices, current market size and future tendency.
从 IDTechEx 访问分析师
所有报告购买订单均包括与一名专家分析师进行 30 分钟的电话交谈，专家分析师将帮助您将报告中的重要发现与您正在处理的业务问题联系起来。这需要在购买报告后的三个月内使用。
更多信息
如果您对这一报告有任何疑问，请随时联系我们的报告团队 research@IDTechEx.com 或致电我们的销售经理：

AMERICAS (USA): +1 617 577 7890
ASIA (Japan and Korea): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
1.EXECUTIVE SUMMARY
1.1.Molecular diagnostics (MDx)
1.2.Drivers for the MDx markets
1.3.What are the benefits and limitations of MDx?
1.4.Working flow of MDx devices
1.5.Key technologies for MDx: overview
1.6.Market forecast for MDx technologies from 2020-2030
1.7.DNA microarray: high-throughput analysis of target regions in the genome
1.8.Synthesis of DNA microarrays
1.9.Key players for DNA microarrays
1.10.Market share of DNA microarrays in 2019
1.11.Market forecast for microarrays devices from 2020-2030
1.12.Polymerase chain reaction (PCR): Process
1.13.Real-Time PCR/ Quantitative PCR (qPCR)
1.14.Digital PCR (dPCR)
1.15.Key players for PCR devices
1.16.Key players for PCR reagents/consumables
1.17.Market share for PCR equipment in 2019
1.18.Market forecast for PCR devices from 2020-2030
1.19.DNA sequencing technology: first generation
1.20.Next generation sequencing (NGS)
1.21.3rd generation sequencing
1.22.Future trends and opportunities
1.23.Market share for DNA sequencers in 2019
1.24.Market forecast for DNA sequencers from 2020-2030
1.25.Miniaturized devices enable molecular diagnostics at point-of-care
1.26.Market drivers for pushing MDx to the point-of-care
1.27.Examples of POC MDx devices
1.28.Cost of cartridges for POC MDx devices
1.29.Key applications for molecular diagnostics
1.30.MDx applications are divided into two categories
1.31.Key players for Human Genetic Tests
1.32.Key players for Microbial Tests
1.33.Market forecast for MDx market segments from 2020-2030
1.34.Market forecast for molecular diagnostics for infectious diseases
1.35.Market forecast for molecular diagnostics for direct-to-consumer
1.36.Market forecast for molecular diagnostics for cancer diagnostics and liquid biopsy
1.37.Market forecast for molecular diagnostics for companion diagnostics
2.INTRODUCTION TO MOLECULAR DIAGNOSTICS
2.1.1.Global healthcare trend
2.1.2.US, Europe and Asia are the key markets
2.1.3.Why the healthcare market is growing
2.1.4.Molecular diagnostics (MDx)
2.1.5.The central dogma: DNA, RNA and Proteins
2.1.6.Key technologies for MDx: overview
2.1.7.Drivers for the MDx markets
2.1.8.Key applications for molecular diagnostics
2.1.9.Clinical market for genomic testing is expanding
2.1.10.All disease is a result of genes interacting with the environment
2.1.11.Testing genetic mutations
2.1.12.Biomarker development in the precision medicine era
2.1.13.What are the benefits and limitations of MDx?
2.1.14.2018: Turning point for MDx
2.2.Genetic Data
2.2.1.Applications of genetic data
2.2.2.Race to build up genetic database and the dilemma for privacy
2.2.3.Global Genetics projects
2.2.4.Population sequencing: backing by governments
2.2.5.Moral and ethical concerns
2.3.Regulations
2.3.1.Regulatory routes to market depend on the target market
2.3.2.EU regulations for medical devices are changing
2.3.3.Changing regulations: Advice to manufacturers
2.3.4.A regulatory road map for diagnostic products in the US
2.3.5.US regulations for diagnostics: CLIA categorizations
3.TECHNOLOGIES OF MOLECULAR DIAGNOSTICS
3.1.1.Introduction to Genome
3.1.2.Genotyping
3.1.3.Gene expression
3.1.4.Genotyping and SNP Analysis
3.1.5.Working flow of MDx devices
3.1.6.Extraction and purification
3.1.7.Amplification: PCR or isothermal amplification
3.1.8.Detection: DNA sequencing vs. DNA probe
3.1.9.Detection methods are being used commercially
3.1.10.Optical detection: fluorescence
3.1.11.Optical detection: colorimetric
3.1.12.Electrochemical detection: with label
3.1.13.Electrochemical detection: label free
3.1.14.The industry moves toward CMOS chips
3.2.Technology: DNA microarrays
3.2.1.DNA microarray: high-throughput analysis of target regions in the genome
3.2.2.Key players for DNA microarrays
3.2.3.Substrate for DNA microarray
3.2.4.Synthesis of DNA microarrays
3.2.5.Synthesis of DNA microarrays: printed methods
3.2.6.Synthesis of DNA microarrays: In-situ synthesis
3.2.7.Synthesis of DNA microarrays: microbeads/ self assembled arrays
3.2.8.Research trend in DNA microarrays: Microfluidic DNA Microarrays
3.2.9.GeneChip® microarrays (Affymetrix, Thermal Fishers)
3.2.10.NimbleGen (Roche): Maskless Array Synthesis
3.2.11.SurePrint technology (Agilent Technologies)
3.2.12.BeadArray Microarray Technology (Illumina)
3.2.13.DualChip (Eppendorf)
3.2.14.NanoChip electronic microarray (Savyon Diagnostics )
3.2.15.DNA microarrays for DNA sequence (exome sequencing)
3.2.16.Limitation of DNA microarray
3.2.17.Revenue of DNA microarrays from 2010 to 2018
3.2.18.Market share of DNA microarrays in 2019
3.2.19.Market forecast for microarrays devices from 2020-2030
3.3.Technology: Polymerase chain reaction (PCR)
3.3.1.Polymerase chain reaction (PCR): Introduction
3.3.2.Polymerase chain reaction (PCR): Process
3.3.3.Trend for PCR technology
3.3.4.Various PCR technologies
3.3.5.Multiplex polymerase chain reaction (mPCR)
3.3.6.Real-Time PCR/ Quantitative PCR (qPCR)
3.3.7.Labelling for qPCR
3.3.8.QuantStudio (Thermal Fisher Scientific): smart PCR
3.3.9.Digital PCR (dPCR)
3.3.10.Digital PCR devices
3.3.11.Droplet Digital PCR (ddPCR, Bio-Rad)
3.3.12.Key players for PCR devices
3.3.13.Key players for PCR reagents/consumables
3.3.14.Isothermal amplification of nucleic acids techniques
3.3.15.Which is the future: isothermal amplification or PCR?
3.3.16.Revenue of PCR devices from 2010 to 2018
3.3.17.Market share for PCR equipment in 2019
3.3.18.Market forecast for PCR devices from 2020-2030
3.4.Technology: DNA sequencing
3.4.1.What's DNA sequencing
3.4.2.DNA sequencing
3.4.3.Applications of DNA sequencing in research and clinical use
3.4.4.DNA sequencing provides insight
3.4.5.DNA sequencing technology: first generation
3.4.6.Capillary Electrophoresis DNA sequencers
3.4.7.Next generation sequencing (NGS)
3.4.8.Second generation sequencing workflows (Illumina)
3.4.9.Key players for second generation sequencing
3.4.10.3rd generation sequencing
3.4.11.Key players for third generation sequencing
3.4.12.DNA sequencers by Thermo Fisher Scientific
3.4.13.DNA sequencers by Oxford nanopore
3.4.14.DNA sequencing supply-chain
3.4.15.Business model: research, clinical genetic tests, direct-to-consumer
3.4.16.Cost for DNA sequencing test
3.4.17.Cost to sequence whole human genome
3.4.18.Future trends and opportunities
3.4.19.Revenue of DNA sequencers from 2010 to 2018
3.4.20.Market share for DNA sequencers in 2019
3.4.21.Market forecast for DNA sequencers from 2020-2030
3.5.Lab-on-a-chip to support molecular diagnostics technologies
3.5.1.What is Lab-on-a-chip (LOC)?
3.5.2.Ideal LOC devices for POC
3.5.3.Lab-on-a-chip applications
3.5.4.Example: the simple chip for low-cost, quantitative, and portable nucleic acid testing
3.5.5.Lab-on-a-chip for digital polymerase chain reaction (dPCR)
3.5.6.Lab-on-a-chip for DNA sequencing
3.5.7.Sample preparation
3.5.8.Biocompatible photoresists
3.5.9.Bio-patterning
3.5.10.Photolithography bio-patterning
3.5.11.Microstamping bio-patterning
3.5.12.Microfluidic patterning
3.5.13.Self-assembly bio-patterning
3.5.14.Active flow control and digital microfluidics
3.5.15.Droplet microfluidics (digital microfluidics)
4.MOLECULAR DIAGNOSTICS AT POINT-OF-CARE
4.1.Miniaturised devices enable molecular diagnostics at point-of-care
4.2.Molecular diagnostics is moving to point-of-care
4.3.Varying importance of molecular diagnostics and point-of-care
4.4.Market drivers for pushing MDx to the point-of-care
4.5.Barriers to success for POC MDx
4.6.The impact of POC MDx on the diagnostics market
4.7.What it takes to win in point-of-care molecular diagnostics
4.8.Examples of POC MDx devices
4.9.POC MDx available and in pipeline
4.10.Costing of cartridges for POC MDx devices
4.11.Examples of disposable cartridge technologies I
4.12.Examples of disposable cartridge technologies II
4.13.Direction for point-of-care molecular diagnostics
4.14.Key trends: multiplexing
4.15.Key trends: connectivity and data management
5.MARKETS FOR MOLECULAR DIAGNOSTICS
5.1.1.Key applications for molecular diagnostics
5.1.2.New markets for molecular diagnostics
5.1.3.MDx applications are divided into two categories
5.1.4.Key players for Human Genetic Tests
5.1.5.Numbers of products with FDA approval for Human Genetic Tests for each key players
5.1.6.Key players for Microbial Tests
5.1.7.Numbers of products with FDA approval for Microbial Tests for each key players
5.2.Infectious diseases diagnosis
5.2.1.What are infectious diseases
5.2.2.Why does it matter
5.2.3.Infectious diseases today
5.2.4.Infectious diseases will lead to pandemic disease
5.2.5.Major infectious threats in 21st Century
5.2.6.Main techniques to diagnose infectious diseases
5.2.7.Microscopy and culture growth methods
5.2.8.Immunoassays
5.2.9.Enzyme-linked immunosorbent assay (ELISA)
5.2.10.Key players in the lateral flow assay market
5.2.11.Molecular diagnostics: Polymerase Chain Reaction (PCR) for infectious disease
5.2.12.Point-of-care molecular diagnostic (POC MDx) will take over the infectious disease market from lateral flow assays (LFA)
5.2.13.Comparison of MDx and immunoassays for infectious diseases
5.2.14.Players in molecular diagnostics for infectious disease detection
5.2.15.Devices: Atlas io system
5.2.16.Devices: Cobas Liat
5.2.17.Devices: Alere i
5.2.18.Devices: Alere q Analyzer
5.2.19.Devices: Spartan Cube
5.2.20.Devices: FilmArray 2.0
5.2.21.Devices: PanNAT system
5.2.22.Devices: GeneXpert Omni
5.2.23.Devices: Spartan Cube
5.2.24.Devices: Q-POC
5.2.25.Additional molecular diagnostic systems
5.2.26.Market forecast for molecular diagnostics for infectious diseases
5.3.Direct-to-consumer (DTC)
5.3.1.23andMe starts DTC business model
5.3.2.Customer motivations for DTC
5.3.3.Considerations when customers purchase DTC
5.3.4.Why DTC diagnostics might not be correct and genetic counsellors are needed
5.3.5.Market forecast for molecular diagnostics for direct-to-consumer
5.4.Liquid Biopsy
5.4.1.Global cancer
5.4.2.Liquid biopsy for cancer: Written in blood
5.4.3.Circulating tumor DNA (ctDNA)
5.4.4.Circulating tumour cells (CTCs)
5.4.5.Liquid biopsy for cancer: Challenges
5.4.6.Project to study the landscape of genomic cancer signal in the blood
5.4.7.Liquid biopsy for lung cancer (OncoCyte)
5.4.8.Early cancer detection by DNA sequencing (GRAIL)
5.4.9.Debate on ctDNA: evolutional or fantasy
5.4.10.Market forecast for molecular diagnostics for cancer diagnostics and liquid biopsy
5.5.Companion Diagnostic
5.5.1.The future: companion diagnostic (CDx)
5.5.2.Some FDA approved CDx products in 2019
5.5.3.Number of FDA approved CDx products (by Oct. 2019)
5.5.4.Market forecast for molecular diagnostics for companion diagnostics
6.MARKET FORECASTS 2020-2030
6.1.Market forecast for MDx technologies from 2020-2030
6.2.Revenue of DNA microarrays from 2010 to 2018
6.3.Market share of DNA microarrays in 2019
6.4.Market forecast for microarrays devices from 2020-2030
6.5.Revenue of PCR devices from 2010 to 2018
6.6.Market share for PCR equipment in 2019
6.7.Market forecast for PCR devices from 2020-2030
6.8.Revenue of DNA sequencers from 2010 to 2018
6.9.Market share for DNA sequencers in 2019
6.10.Market forecast for DNA sequencers from 2020-2030
6.11.Market forecast for MDx market segments from 2020-2030
6.12.Market forecast for molecular diagnostics for infectious diseases
6.13.Market forecast for molecular diagnostics for direct-to-consumer
6.14.Market forecast for molecular diagnostics for cancer diagnostics and liquid biopsy
6.15.Market forecast for molecular diagnostics for companion diagnostics
7.COMPANY PROFILES
 

About IDTechEx reports

What are the qualifications of the people conducting IDTechEx research?

Content produced by IDTechEx is researched and written by our technical analysts, each with a PhD or master's degree in their specialist field, and all of whom are employees. All our analysts are well-connected in their fields, intensively covering their sectors, revealing hard-to-find information you can trust.

How does IDTechEx gather data for its reports?

By directly interviewing and profiling companies across the supply chain. IDTechEx analysts interview companies by engaging directly with senior management and technology development executives across the supply chain, leading to revealing insights that may otherwise be inaccessible.
 
Further, as a global team, we travel extensively to industry events and companies to conduct in-depth, face-to-face interviews. We also engage with industry associations and follow public company filings as secondary sources. We conduct patent analysis and track regulatory changes and incentives. We consistently build on our decades-long research of emerging technologies.
 
We assess emerging technologies against existing solutions, evaluate market demand and provide data-driven forecasts based on our models. This provides a clear, unbiased outlook on the future of each technology or industry that we cover.

What is your forecast methodology?

We take into account the following information and data points where relevant to create our forecasts:
  • Historic data, based on our own databases of products, companies' sales data, information from associations, company reports and validation of our prior market figures with companies in the industry.
  • Current and announced manufacturing capacities
  • Company production targets
  • Direct input from companies as we interview them as to their growth expectations, moderated by our analysts
  • Planned or active government incentives and regulations
  • Assessment of the capabilities and price of the technology based on our benchmarking over the forecast period, versus that of competitive solutions
  • Teardown data (e.g. to assess volume of materials used)
  • From a top-down view: the total addressable market
  • Forecasts can be based on an s-curve methodology where appropriate, taking into account the above factors
  • Key assumptions and discussion of what can impact the forecast are covered in the report.

How can I be confident about the quality of work in IDTechEx reports?

Based on our technical analysts and their research methodology, for over 25 years our work has regularly received superb feedback from our global clients. Our research business has grown year-on-year.
 
Recent customer feedback includes:
"It's my first go-to platform"
- Dr. Didi Xu, Head of Foresight - Future Technologies, Freudenberg Technology Innovation
 
"Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
- Ralf Hug, Global Head of Product Management & Marketing, Marquardt

What differentiates IDTechEx reports?

Our team of in-house technical analysts immerse themselves in industries over many years, building deep expertise and engaging directly with key industry players to uncover hard-to-find insights. We appraise technologies in the landscape of competitive solutions and then assess their market demand based on voice-of-the-customer feedback, all from an impartial point of view. This approach delivers exceptional value to our customers—providing high-quality independent content while saving customers time, resources, and money.

Why should we pick IDTechEx research over AI research?

A crucial value of IDTechEx research is that it provides information, assessments and forecasts based on interviews with key people in the industry, assessed by technical experts. AI is trained only on content publicly available on the web, which may not be reliable, in depth, nor contain the latest insights based on the experience of those actively involved in a technology or industry, despite the confident prose.

How can I justify the ROI of this report?

Consider the cost of the IDTechEx report versus the time and resources required to gather the same quality of insights yourself. IDTechEx analysts have built up an extensive contact network over many years; we invest in attending key events and interviewing companies around the world; and our analysts are trained in appraising technologies and markets.
 
Each report provides an independent, expert-led technical and market appraisal, giving you access to actionable information immediately, rather than you having to spend months or years on your own market research.

Can I speak to analysts about the report content?

All report purchases include up to 30 minutes of telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

What is the difference between a report and subscription?

A subscription from IDTechEx can include more reports, access to an online information platform with continuously updated information from our analysts, and access to analysts directly.

Before purchasing, I have some questions about the report, can I speak to someone?

Please email research@idtechex.com stating your location and we will quickly respond.

About IDTechEx

Who are IDTechEx's customers?

IDTechEx has served over 35,000 customers globally. These range from large corporations to ambitious start-ups, and from Governments to research centers. Our customers use our work to make informed decisions and save time and resources.

Where is IDTechEx established?

IDTechEx was established in 1999, and is headquartered in Cambridge, UK. Since then, the company has significantly expanded and operates globally, having served customers in over 80 countries. Subsidiary companies are based in the USA, Germany and Japan.

Questions about purchasing a report

How do I pay?

In most locations reports can be purchased by credit card, or else by direct bank payment.

How and when do I receive access to IDTechEx reports?

When paying successfully by credit card, reports can be accessed immediately. For new customers, when paying by bank transfer, reports will usually be released when the payment is received. Report access will be notified by email.

How do I assign additional users to the report?

Users can be assigned in the report ordering process, or at a later time by email.

Can I speak to someone about purchasing a report?

Please email research@idtechex.com stating your location and we will quickly respond.
 
到 2030 年，分子诊断市场的规模将达到 200 亿美元

报告统计信息

幻灯片 311
预测 2030
 

Customer Testimonial

quote graphic
"IDTechEx consistently provides well-structured and comprehensive research reports, offering a clear and holistic view of key trends... It's my first go-to platform for quickly exploring new topics and staying updated on industry advancements."
Head of Foresight - Future Technologies
Freudenberg Technology Innovation SE & Co. KG
 
 
 

Subscription Enquiry